SCHEMBL647326

SCHEMBL647326

C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(O)C[C@@]2(C)[C@H]1C[C@@H](O)[C@]2(O)C(=O)CO

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 8/20 0.84
▸ HIF1A Q16665 8/20 0.72
▸ PGR P06401 6/20 0.72
▸ HSD17B10 Q99714 5/20 0.72
▸ CYP3A4 P08684 5/20 0.72
▸ ABCB11 O95342 2/20 0.72
▸ NR3C2 P08235 2/20 0.72
▸ AR P10275 2/20 0.72
▸ CYP2C19 P33261 2/20 0.72
▸ TNF P01375 1/20 0.72
▸ IL6 P05231 1/20 0.72
▸ SERPINA6 P08185 1/20 0.72
▸ GLUL P15104 1/20 0.72
▸ ADAM17 P78536 1/20 0.72
▸ GPBAR1 Q8TDU6 1/20 0.72
▸ LMNA P02545 4/20 0.65
▸ NR1I2 O75469 1/20 0.65
▸ CNR1 P21554 1/20 0.65
▸ CYP2C9 P11712 3/20 0.62
▸ NFKB1 P19838 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3775851 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL4726540 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL12313064 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL23832187 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL647327 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL25129199 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL24861840 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL24622464 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL21293123 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4
SCHEMBL1753572 1.00 NR3C1 (0.84) NR3C1HIF1APGRHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118085006-A Method for large-scale preparation of budesonide 杭州新曦科技有限公司 2024-05-28 — — CN claimed
EP-2108653-B2 Process for preparing budesonide IND CHIMICA SRL (IT) 2016-08-31 — — EP claimed
EP-2108653-B1 Process for preparing budesonide IND CHIMICA SRL (IT) 2013-08-07 — — EP claimed
EP-2262823-B1 PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES FARMABIOS SPA (IT) 2013-01-23 — — EP claimed
US-8119793-B2 Process for preparing budesonide INDUSTRIALE CHIMICA S.R.L. (IT) 2012-02-21 — — US claimed
US-20100331539-A1 PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES FARMABIOS S.P.A. (IT) 2010-12-30 — — US claimed
EP-2265628-A1 PURIFICATION OF AIR SENSITIVE STEROIDS Sicor, Inc. (US) 2010-12-29 — — EP claimed
EP-2262823-A2 PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES Farmabios S.p.A. (IT) 2010-12-22 — — EP claimed
US-20090259037-A1 PROCESS FOR PREPARING BUDESONIDE INDUSTRIALE CHIMICA S.R.L. (IT) 2009-10-15 — — US claimed
EP-2108653-A1 Process for preparing budesonide INDUSTRIALE CHIMICA S.r.l. (IT) 2009-10-14 — — EP claimed
WO-2009117120-A1 PURIFICATION OF AIR SENSITIVE STEROIDS SICOR INC. (US) 2009-09-24 — — WO claimed
US-20090240049-A1 Purification of air sensitive steroids SICOR INC. 2009-09-24 — — US claimed
WO-2009112557-A2 PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES FARMABIOS S.P.A. (IT) 2009-09-17 — — WO claimed
WO-2005044759-A2 ACETALIZATION PROCESS FOR PREPARATION OF STEROID COMPOUNDS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2005-05-19 — — WO claimed
US-20250302990-A1 ENHANCING NON-VIRAL DNA DELIVERY AND EXPRESSION SPARK THERAPEUTICS, INC. 2025-10-02 — — US disclosed
EP-4583861-A1 ENHANCING NON-VIRAL DNA DELIVERY AND EXPRESSION Spark Therapeutics, Inc. (US) 2025-07-16 — — EP disclosed
WO-2025101692-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR ANOMALIES THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-05-15 — — WO disclosed
US-4820700-A ANTIINFLAMMATORY AGENTS AKTIEBOLAGET DRACO (SE) 1989-04-11 — — US disclosed
EP-0143764-A1 Novel androstane-17 beta-carboxylic acid esters, a process and intermediates for their preparation, composition and method for the treatment of inflammatory conditions Aktiebolaget Draco (SE) 1985-06-05 — — EP disclosed
US-4137311-A CORTICOSTEROIDS, METAL ADDUCTS OF BIS(2-PYRIDYL-1-OXIDE)-DISULFIDE; DERMATITIS, ANTIINFLAMMATORY WILLIAM H. RORER, INC. (US) 1979-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240049-A1 Purification of air sensitive steroids CYP17A1, CYP11B1, CYP11B2 NR3C1 31/4885HIF1A 493/4885PGR 2988/4885
US-20250302990-A1 ENHANCING NON-VIRAL DNA DELIVERY AND EXPRESSION STING1, IFNAR1, IRF3 NR3C1 1353/4885HIF1A 549/4885PGR 2044/4885
US-20090259037-A1 PROCESS FOR PREPARING BUDESONIDE CYP11B2, CYP11B1, HSD11B2 NR3C1 38/4885HIF1A 744/4885PGR 2246/4885
US-20100331539-A1 PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES CYP17A1, CYP21A2, CYP11B1 NR3C1 19/4885HIF1A 2713/4885PGR 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback